Recent Analysts’ Ratings Updates for BioNTech (BNTX)

A number of research firms have changed their ratings and price targets for BioNTech (NASDAQ: BNTX):

• 6/1/2026 – BioNTech had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 5/27/2026 – BioNTech was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $135.00 price target on the stock, up from $117.00.
• 5/23/2026 – BioNTech was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/21/2026 – BioNTech is now covered by Sanford C. Bernstein. They set a “market perform” rating and a $96.00 price target on the stock.
• 5/21/2026 – BioNTech was upgraded by Sanford C. Bernstein to “hold”.
• 5/12/2026 – BioNTech had its price target lowered by Berenberg Bank from $155.00 to $140.00. They now have a “buy” rating on the stock.
• 5/9/2026 – BioNTech was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/6/2026 – BioNTech had its price target lowered by Canaccord Genuity Group Inc. from $171.00 to $158.00. They now have a “buy” rating on the stock.
• 5/6/2026 – BioNTech had its price target lowered by Wells Fargo & Company from $150.00 to $140.00. They now have an “overweight” rating on the stock.
• 4/27/2026 – BioNTech had its “buy” rating reaffirmed by HC Wainwright. They now have a $130.00 price target on the stock.
• 4/13/2026 – BioNTech had its “buy” rating reaffirmed by Berenberg Bank.
• 4/10/2026 – BioNTech had its price target raised by Morgan Stanley from $125.00 to $126.00. They now have an “overweight” rating on the stock.
• 4/8/2026 – BioNTech had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insider Transactions at BioNTech

In other BioNTech news, COO Sierk Poetting sold 50,000 shares of the company’s stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the completion of the transaction, the chief operating officer owned 399,387 shares in the company, valued at approximately $44,156,226.72. This represents a 11.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 19.20% of the company’s stock.

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.